Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

PharmaRelations ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 7.2% 7.2%   Bankruptcy risk   3.3% 4.0% 2.2% 1.2% 1.7% 0.9% 7.6% 7.5%   Credit score (0-100)   56 51 66 81 73 86 32 33   Credit rating   BBB BBB BBB A A A BB BB   Credit limit (kDKK)   0.0 0.0 0.3 315.9 15.0 798.7 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   6,548 0 0 0 0 0 0 0   Gross profit   5,138 8,595 14,606 20,105 23,600 23,252 0.0 0.0   EBITDA   705 666 2,060 3,370 966 1,033 0.0 0.0   EBIT   634 595 1,989 3,298 894 961 0.0 0.0   Pre-tax profit (PTP)   627.3 580.5 1,938.6 3,273.8 865.7 896.6 0.0 0.0   Net earnings   488.4 429.9 1,493.9 2,553.5 674.6 699.4 0.0 0.0   Pre-tax profit without non-rec. items   627 581 1,939 3,274 866 897 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   470 900 2,394 4,948 5,622 6,322 6,272 6,272   Interest-bearing liabilities   1,900 1,606 29.7 30.2 56.8 17.8 0.0 0.0   Balance sheet total (assets)   3,697 4,999 8,326 9,055 8,587 9,990 6,272 6,272   Net Debt   901 2.9 -3,654 -2,017 -403 -1,222 -6,272 -6,272     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   6,548 0 0 0 0 0 0 0   Net sales growth   0.0% -100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   5,138 8,595 14,606 20,105 23,600 23,252 0.0 0.0   Gross profit growth   28.2% 67.3% 69.9% 37.7% 17.4% -1.5% -100.0% 0.0%   Employees   5 10 10 20 29 28 0 0   Employee growth %   0.0% 100.0% 0.0% 100.0% 45.0% -3.4% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   3,697 4,999 8,326 9,055 8,587 9,990 6,272 6,272   Balance sheet change%   55.0% 35.2% 66.6% 8.8% -5.2% 16.3% -37.2% 0.0%   Added value   705.3 666.2 2,060.5 3,369.5 965.7 1,032.7 0.0 0.0   Added value %   10.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -143 -143 -143 -143 -143 -143 0 0   Net sales trend   0.0 -1.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 2.0 3.0 4.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   10.8% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   9.7% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   12.3% 6.9% 13.6% 16.4% 3.8% 4.1% 0.0% 0.0%   Net Earnings %   7.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   8.5% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   9.6% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   20.8% 13.7% 29.9% 38.0% 10.1% 10.3% 0.0% 0.0%   ROI %   31.7% 24.4% 80.7% 89.1% 16.8% 16.0% 0.0% 0.0%   ROE %   34.2% 62.7% 90.7% 69.6% 12.8% 11.7% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   12.7% 18.0% 28.8% 54.6% 65.5% 63.3% 100.0% 100.0%   Relative indebtedness %   49.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   34.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   127.7% 0.4% -177.3% -59.9% -41.7% -118.3% 0.0% 0.0%   Gearing %   403.8% 178.4% 1.2% 0.6% 1.0% 0.3% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.7% 0.8% 6.2% 81.2% 65.9% 173.5% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   2.5 1.9 1.4 2.1 2.8 2.7 0.0 0.0   Current Ratio   2.5 1.9 1.4 2.1 2.8 2.7 0.0 0.0   Cash and cash equivalent   998.7 1,603.4 3,683.8 2,047.5 459.9 1,239.7 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   127.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   40.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   50.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   1,964.1 2,139.7 2,077.3 4,653.1 5,304.2 6,109.2 0.0 0.0   Net working capital %   30.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   1,310 0 0 0 0 0 0 0   Added value / employee   141 67 206 168 33 37 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   141 67 206 168 33 37 0 0   EBIT / employee   127 59 199 165 31 34 0 0   Net earnings / employee   98 43 149 128 23 25 0 0